Monday, October 5, 2015

Ocular treatment likely to become first Gene Therapy approved in US

(c) nature.com
Spark Therapeutics has announced positive results from the Phase 3 pivotal trial of its lead gene therapy product candidate, SPK-RPE65, for the treatment of RPE65-mediated inherited retinal dystrophies (IRDs). These results represent the first successful randomized, controlled Phase 3 trial ever completed in gene therapy for a genetic disease.


Wednesday, September 30, 2015

Study Finds Anti-VEGF Therapy Safer Before Steroids for Retinal Vein Occlusion

In results from a new study that was presented at EURETINA, Aflibercept and ranibizumab were found to be safer than dexamethasone intravitreal implants for the treatment of central retinal vein occlusion.

Tuesday, September 29, 2015

First patient receives potential new treatment for wet age-related macular degeneration (AMD)

A pioneering trial of a new treatment derived from stem cells for people with wet age-related macular degeneration (AMD) has commenced at Moorfields Eye Hospital following a successful operation on a patient.

Wednesday, September 23, 2015

Mediterranean Diet May Prevent Diabetic Retinopathy

(c) geneticliteracyproject.org
The Mediterranean diet may protect against diabetic retinopathy, according to a study published in Diabetes Care.

Tuesday, September 1, 2015

When do you recommend eye exam for a child with type 1 diabetes?

A new study suggests that the occurrence of advanced forms of a diabetic eye disease remains low among children living with diabetes, regardless of how long they have had the disease or their ability to keep blood sugar levels controlled. Researchers are therefore recommending that most children with type 1 diabetes delay annual diabetic retinopathy screenings until age 15, or 5 years after their diabetes diagnosis, whichever occurs later.

Friday, August 28, 2015

AMD likely to be more in people with deficient vitamin D status

A multi-institutional team reports that vitamin D may play a significant role in eye health, specifically in the possible prevention of age-related macular degeneration, or AMD, among women who are more genetically prone to developing the sight-damaging disease.

In a paper published in JAMA Ophthalmology online, the team found that women who are deficient in vitamin D and have a specific high-risk genotype are 6.7 times more likely to develop AMD than women with sufficient vitamin D status and no high risk genotype.

Monday, August 24, 2015

RetroSense Therapeutics Gets Approval for Clinical Trials in Retinitis Pigmentosa

(c) nature.com
RetroSense Therapeutics’ Investigational New Drug (IND) application for gene therapy based clinical trial for their product RST-001 has received clearance from the US Food and Drug Administration. RetroSense is developing RST-001 for the treatment of retinitis pigmentosa, a genetic condition that leads to the progressive degeneration of rod and cone photoreceptors (cells found in the retina that sense light), resulting in severe vision loss and blindness. With its IND now in effect, RetroSense expects to initiate a Phase I/II clinical trial by year-end in order to evaluate the safety and, potentially, efficacy of RST-001.